The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature

Abdulrahman Al-Abdulmalek; Reem Al-Suliman; Mohammad Abu-Tineh; Mostafa Ali; Mohamed A Yassin

doi:10.1002/ccr3.7087

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature

Clin Case Rep. 2023 Mar 17;11(3):e7087. doi: 10.1002/ccr3.7087. eCollection 2023 Mar.

Authors

Abdulrahman Al-Abdulmalek¹, Reem Al-Suliman², Mohammad Abu-Tineh², Mostafa Ali³, Mohamed A Yassin²

Affiliations

¹ Department of Internal Medicine Hamad Medical Corporation Doha Qatar.
² Department of Medical Oncology National Center for Cancer Care and Research Doha Qatar.
³ Department of Radiology Hamad Medical Corporation Doha Qatar.

Abstract

The relationship between chronic myelogenous leukemia (CML) and tuberous sclerosis (TS) is unusual and uncommon. Here, we report a 24-year-old woman diagnosed with TS and later identified with CML, as the second case reported with such coexistence, treated with Nilotinib. This article proposes a hypothesis to explain the association. Therefore, we propose Nilotinib for the treatment of patients with such coexisting diseases. Further studies are warranted to reveal the dynamics between these conditions.

Keywords: CML; tuberous sclerosis; tyrosine kinase inhibitors.

Publication types

Case Reports